245 related articles for article (PubMed ID: 29525332)
1. Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications.
Packer M
JACC Heart Fail; 2018 Jun; 6(6):445-451. PubMed ID: 29525332
[TBL] [Abstract][Full Text] [Related]
2. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
Bonora E; Cigolini M
Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
[TBL] [Abstract][Full Text] [Related]
3. Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk.
Sano M
J Cardiol; 2019 Jan; 73(1):28-32. PubMed ID: 30318179
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
Li L; Li S; Deng K; Liu J; Vandvik PO; Zhao P; Zhang L; Shen J; Bala MM; Sohani ZN; Wong E; Busse JW; Ebrahim S; Malaga G; Rios LP; Wang Y; Chen Q; Guyatt GH; Sun X
BMJ; 2016 Feb; 352():i610. PubMed ID: 26888822
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
6. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.
Kappel BA; Marx N; Federici M
Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):697-705. PubMed ID: 26164634
[TBL] [Abstract][Full Text] [Related]
7. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P
Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
[TBL] [Abstract][Full Text] [Related]
8. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
Gooßen K; Gräber S
Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
[TBL] [Abstract][Full Text] [Related]
9. Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design.
Imazu M; Nakano A; Ito S; Hamasaki T; Kitakaze M;
Cardiovasc Drugs Ther; 2019 Jun; 33(3):363-370. PubMed ID: 30850916
[TBL] [Abstract][Full Text] [Related]
10. Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity? Clues From Laboratory Models and Clinical Trials.
Packer M
Circ Res; 2018 Mar; 122(7):928-932. PubMed ID: 29436388
[TBL] [Abstract][Full Text] [Related]
11. Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk.
Vaduganathan M; Singh A; Sharma A; Januzzi JL; Scirica BM; Butler J; Zannad F; McGuire DK; Cannon CP; Bhatt DL
Am J Cardiol; 2020 May; 125(10):1577-1581. PubMed ID: 32245636
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
Kaneko M; Narukawa M
Ann Pharmacother; 2017 Jul; 51(7):570-576. PubMed ID: 28622738
[TBL] [Abstract][Full Text] [Related]
14. The Alchemist's Nightmare: Might Mesenchymal Stem Cells That Are Recruited to Repair the Injured Heart Be Transformed Into Fibroblasts Rather Than Cardiomyocytes?
Packer M
Circulation; 2018 May; 137(19):2068-2073. PubMed ID: 29735591
[TBL] [Abstract][Full Text] [Related]
15. The safety of gliptins : updated data in 2018.
Scheen AJ
Expert Opin Drug Saf; 2018 Apr; 17(4):387-405. PubMed ID: 29468916
[TBL] [Abstract][Full Text] [Related]
16. Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines.
Packer M
Cardiovasc Diabetol; 2018 Jan; 17(1):9. PubMed ID: 29310647
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Raschi E; Poluzzi E; Koci A; Antonazzo IC; Marchesini G; De Ponti F
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):380-6. PubMed ID: 27067162
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl Peptidase-4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study.
Cobretti MR; Bowman B; Grabarczyk T; Potter E
Pharmacotherapy; 2018 Mar; 38(3):334-340. PubMed ID: 29364549
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
20. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
